Skip to main content
Clinical Trials/ITMCTR2200006549
ITMCTR2200006549
Recruiting
未知

A controlled clinical study to evaluate the efficacy of Tibetan medicine in the prevention and treatment of asymptomatic COVID-19 infection and mild COVID-19 patients

Tibetan Hospital Mentsee Khang of Tibet Autonomous Region0 sitesTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Tibetan Hospital Mentsee Khang of Tibet Autonomous Region
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Tibetan Hospital Mentsee Khang of Tibet Autonomous Region

Eligibility Criteria

Inclusion Criteria

  • 1\. Meet the novel coronavirus diagnostic criteria for asymptomatic infection
  • Tibetan Medicine Diagnosis and Treatment Plan for COVID\-19 in Tibet Autonomous Region (trial version 3\).
  • The COVID\-19 nucleic acid test was positive. No clinical manifestations or imaging manifestations of pneumonia.
  • 2\. Meet the novel coronavirus diagnostic criteria for mild coronavirus;
  • Mild cases may present with fever, dry cough, headache, sore throat, etc. The clinical symptoms were mild, and imaging showed no signs of pneumonia.
  • 2\.1 General Inspection
  • In the early stage of the disease, the total number of peripheral blood white blood cells is normal or decreased, and the lymphocyte count is decreased. Some patients may have increased liver enzymes, lactate dehydrogenase, muscle enzymes, myoglobin, troponin and ferritin. C\-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were elevated in most patients, while procalcitonin (PCT) was normal. In severe and critical patients, D\-dimer increased, peripheral blood lymphocytes decreased progressively, and inflammatory factors increased.
  • 2\.2 Etiological and serological examination
  • 2\.2\.1 Pathogenic examination: Test novel coronavirus nucleic acid on nose and oropharyngeal swabs, sputum and other lower respiratory tract secretions, and feces by nucleic acid amplification test. Nucleic acid detection will be affected by the course of disease, specimen collection, detection process, detection reagents and other factors. In order to improve the accuracy of detection, the collection of specimens should be standardized, and specimens should be submitted to test as soon as possible after collection.
  • 2\.2\.2 Serological examination: novel coronavirus specific IgM and IgG antibodies are positive, and the positive rate within 1 week after onset is low.

Exclusion Criteria

  • 1\. Patients with serious diseases of heart, brain, liver, kidney and hematopoietic system;
  • 2\. Allergic constitution or allergic to a variety of drugs.

Outcomes

Primary Outcomes

Not specified

Similar Trials